RXSIGHT DEADLINEALERT: Bragar Eagel & Squire, P.C. Reminds RXST Investors that a Class Action Lawsuit Has Been Filed Against RxSight, Inc. and Encourages Investors to Contact the Firm Before September 22nd

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false or misleading statements regarding its financial performance and product demand during the specified class period [7]. Allegation Details - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization of its products [7]. - It is alleged that RxSight overstated the demand for its products, which contributed to the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [7]. Financial Impact - On July 8, 2025, RxSight reported preliminary second quarter financial results showing significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [7]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [7]. - Following this announcement, RxSight's stock price fell nearly 38% [7]. Next Steps - Investors who purchased RxSight shares during the class period and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4].